CareDx, Inc (CDNA) AI Stock Analysis

CareDx, Inc. discovers, develops, and distributes diagnostic solutions tailored for transplant patients and their caregivers worldwide. Headquartered in South San Francisco, California, the company offers flagship surveillance products including AlloSure Kidney and AlloSure Heart, which use donor-derived cell-free DNA for post-transplant surveillance. Its portfolio also includes AlloMap Heart gene expression tests, AlloSure Lung, TruSight HLA next-generation sequencing typing, Olerup SSP, and AlloSeq Tx. CareDx provides transplant patient management software through Ottr and commercializes the iBox predictive software platform with Cibiltech SAS, while collaborating with partners such as Illumina, Inc.

Revenue grew from $296.4M in FY2021 to $321.8M in FY2022, before falling 12.9% to $280.3M in FY2023. Revenue recovered to $333.8M in FY2024 and reached $379.8M in FY2025, reflecting a 5-year revenue CAGR of 14.6% from FY2020 to FY2025. Gross margins remained stable between 63.6% and 67.6% over this period. Net income moved from -$30.7M in FY2021 to -$190.3M in FY2023, turned positive at $52.5M in FY2024, and recorded -$21.4M in FY2025. In the trailing twelve months ended June 30, 2026, revenue totaled $458.1M with quarterly revenue growth of 52.2% year-over-year, delivering a profit margin of 24.2% and EPS of $2.08.

As of June 30, 2026, CareDx held $373.6M in cash and short-term investments against total debt of $19.2M, resulting in net cash of $354.4M. Its current ratio was 4.58 and debt-to-equity stood at 0.05. Shareholders' equity totaled $425.6M out of $533.0M in total assets. During FY2025, operating cash flow was $42.0M and free cash flow was $36.1M. Capital expenditures were $5.9M, while the company directed $87.8M toward share buybacks.

CareDx trades at a trailing P/E of 30.8x and a forward P/E of 156.2x, compared to medians of 24.6x and 17.3x for its US-listed Healthcare peers. Its enterprise value to EBITDA ratio is 157.8x, above the peer median of 12.0x, while price-to-sales stands at 7.2x versus the peer median of 4.1x. The stock closed at $64.00 on October 16, 2026, yielding a 1-year return of 327.0%, outperforming the S&P 500 SPY return of 16.8%. Over five years, the stock returned -9.9% compared to 83.0% for the benchmark.

Wall Street coverage comprises 5 Strong Buy and 2 Hold ratings, with no Buy, Sell, or Strong Sell ratings. The mean price target of $61.67 sits 3.6% below the last close of $64.00. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $495.1M and EPS of $1.20, representing EPS growth of 106.6%. Across the last 4 quarters, CareDx recorded 4 EPS beats. The next earnings release date is October 29, 2026.

This page is an AI-written research summary of CareDx, Inc (CDNA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CDNA income statement, CDNA balance sheet, CDNA key metrics, CDNA analyst forecast, CDNA chart. See the CDNA stock overview for the latest quote and news.